Moreover, down‐regulation of H19 combined with Gefitinib administration significantly improved down‐regulation of H19 treatment alone in controlling NSCLC development, which participated in the activation of PTEN signalling pathway in NSCLC in vivo. The gene discussed is H19; the disease is non-small cell lung carcinoma.